Van ECK Associates Corp Acquires New Position in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Van ECK Associates Corp acquired a new stake in iRhythm Technologies, Inc. (NASDAQ:IRTCGet Rating) in the third quarter, Holdings Channel reports. The firm acquired 390 shares of the company’s stock, valued at approximately $49,000.

A number of other institutional investors have also recently made changes to their positions in IRTC. Focused Wealth Management Inc acquired a new position in shares of iRhythm Technologies in the third quarter valued at approximately $50,000. First Horizon Advisors Inc. acquired a new position in shares of iRhythm Technologies in the second quarter valued at approximately $53,000. Point72 Hong Kong Ltd acquired a new position in shares of iRhythm Technologies in the second quarter valued at approximately $85,000. Captrust Financial Advisors lifted its stake in iRhythm Technologies by 92.0% in the second quarter. Captrust Financial Advisors now owns 935 shares of the company’s stock worth $101,000 after acquiring an additional 448 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in iRhythm Technologies by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,126 shares of the company’s stock worth $122,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 98.96% of the company’s stock.

Insider Activity at iRhythm Technologies

In related news, CEO Quentin S. Blackford sold 12,699 shares of the company’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $122.40, for a total value of $1,554,357.60. Following the completion of the sale, the chief executive officer now owns 89,280 shares in the company, valued at approximately $10,927,872. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.64% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IRTC. Needham & Company LLC decreased their price target on shares of iRhythm Technologies from $185.00 to $140.00 and set a “buy” rating for the company in a research note on Wednesday, November 2nd. Morgan Stanley decreased their price target on shares of iRhythm Technologies from $165.00 to $128.00 and set an “overweight” rating for the company in a research note on Friday, January 6th. Oppenheimer decreased their price target on shares of iRhythm Technologies from $175.00 to $166.00 in a research note on Wednesday, November 2nd. Citigroup decreased their price target on shares of iRhythm Technologies from $144.00 to $110.00 and set a “neutral” rating for the company in a research note on Monday, December 12th. Finally, StockNews.com downgraded shares of iRhythm Technologies from a “hold” rating to a “sell” rating in a research note on Friday, January 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $152.00.

iRhythm Technologies Stock Down 0.2 %

Shares of NASDAQ:IRTC opened at $99.90 on Friday. The company has a market capitalization of $3.01 billion, a PE ratio of -23.12 and a beta of 1.44. The company has a current ratio of 3.42, a quick ratio of 3.25 and a debt-to-equity ratio of 0.15. iRhythm Technologies, Inc. has a twelve month low of $85.74 and a twelve month high of $169.54. The firm has a 50 day simple moving average of $99.53 and a 200-day simple moving average of $123.62.

iRhythm Technologies (NASDAQ:IRTCGet Rating) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.19. iRhythm Technologies had a negative net margin of 33.79% and a negative return on equity of 39.31%. The business had revenue of $103.88 million during the quarter, compared to the consensus estimate of $106.43 million. On average, equities analysts predict that iRhythm Technologies, Inc. will post -3.82 EPS for the current fiscal year.

iRhythm Technologies Profile

(Get Rating)

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Featured Articles

Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRhythm Technologies, Inc. (NASDAQ:IRTCGet Rating).

Institutional Ownership by Quarter for iRhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.